{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-046247","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.815589+00:00","generated_at":"2026-06-04T00:10:13.218675+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Century Therapeutics updates pipeline; CNTY-101 shows durable responses, no allo-rejection in Ph1","bullets":["CNTY-101 (CD19 iNK) in Ph1 ELiPSE-1 shows favorable safety, 2 CRs including 6-month durable CR, no allo-rejection.","Plan to initiate Ph1 CALiPSO-1 trial in SLE in H1 2024; initial data expected by YE 2024.","Cash, cash equivalents, and investments of $261.8M at end of Q4 2023; runway into 2026.","Platform includes Allo-Evasion edits enabling repeat dosing without lymphodepletion; advancing iNK and γδ iT cell programs.","Additional ELiPSE-1 data expected mid-2024; pursuing additional autoimmune health authority filings in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-046247","json":"https://secwatch.observer/filing/0001104659-24-046247.json","markdown":"https://secwatch.observer/filing/0001104659-24-046247.md","text":"https://secwatch.observer/filing/0001104659-24-046247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924046247/0001104659-24-046247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924046247/tm2411557d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:10:13.218675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}